Myelodysplastic Syndromes: From Inflammatory to Therapeutic Approaches (Closed)

A topical collection in Journal of Clinical Medicine (ISSN 2077-0383). This collection belongs to the section "Hematology".

Viewed by 1404

Editor

Department of Hematology, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Bobigny, France
Interests: MDS; CMML; Treg; ruxolitinib; AML progression

Topical Collection Information

Dear Colleagues,

Impaired function of immune cells and aberrant inflammatory response of the immune system is frequently observed for patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Increased secretion of inflammatory cytokines, including tumor necrosis factor-(TNF)-α and interferon (IF)-γ, contributes to cell death of myeloid precursor cells and triggers transformation to acute myeloid leukemia (AML). For CMML patients, a phospho-STAT5 hypersensitive response to GM-CSF has been identified that is positively correlated with high-risk disease. Altered function of cytotoxic, regulatory (Treg), helper (Th17) T cells, and natural killer (NK) cells contribute to cytopenias and disease progression. Autoimmune disorders (AD) observed for MDS and CMML patients include vasculitis, seronegative polyarthritis, relapsing polychondritis, or neutrophilic dermatosis. In a subset of patients, cytopenias are the consequence of autoreactive cytotoxic T cells and respond to immunosuppressive treatment (IST). Interestingly, despite IST, other drugs are of interest by treating MDS and CMML-associated AD and inflammatory response as the hypomethylating agent azacytidine improves cytopenias, delays disease progression, and controls AD by sparing corticosteroids and other immunosuppressive drugs. The immunomodulatory drug lenalidomide improves anemia in specific subtypes of MDS and inhibitors of the JAK-STAT pathway should be evaluated for the treatment of selected MDS and CMML patients.

Prof. Dr. Thorsten Braun
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • MDS
  • CMML
  • AML
  • Autoimmune disorders
  • Azacytidine
  • Ruxolitinib
  • Imids
  • Cytokines
  • T cells

Published Papers (1 paper)

2023

10 pages, 3535 KiB  
Article
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level
J. Clin. Med. 2023, 12(18), 5865; https://doi.org/10.3390/jcm12185865 - 09 Sep 2023
Cited by 1 | Viewed by 688
Abstract
Quality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb–QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using [...] Read more.
Quality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb–QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using scores of 0 (normal), 1 (mild/moderate), or 2 (poor). They also evaluated their health using a visual analogue scale, scoring from 0 (poor) to 100 (excellent). The anemia subgroups were: none/normal (Hb ≥ 12.5 g/dL), mild (10 ≤ Hb < 12.5), moderate (9 ≤ Hb < 10), severe (8 ≤ Hb < 9), or very severe (Hb < 8). LR-MDS patients (n = 127) and inpatient controls (n = 141) participated. The anemic patients had a poor QoL and the MDS patients had a lower QoL with a lower Hb. The controls had no QoL difference among the various anemia subgroups. In addition, the MDS QoL sharply decreased with an Hb of < 9. The MDS patients showed a wide QoL variability, i.e., different QoL scores in the same Hb subgroup, suggesting that other factors affect QoL (e.g., age and comorbidities). After 1 year (n = 61), the QoL was still poor for most MDS patients (including 27 patients with an increased Hb). In summary: (1) a poor QoL in MDS-anemia is non-linear, suggesting other influencing factors on QoL. (2) The sharp QoL drop with Hb < 9 g/dL challenges the transfusion Hb threshold. (3) The QoL in anemic MDS patients might differ from that in non-MDS patients. (4) Raising Hb, while recommended, does not guarantee an improved QoL. Full article
Show Figures

Figure 1

Back to TopTop